Last reviewed · How we verify
FDC therapy — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
FDC therapy (FDC therapy) — Novartis Pharmaceuticals.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| FDC therapy TARGET | FDC therapy | Novartis Pharmaceuticals | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- FDC therapy CI watch — RSS
- FDC therapy CI watch — Atom
- FDC therapy CI watch — JSON
- FDC therapy alone — RSS
Cite this brief
Drug Landscape (2026). FDC therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/fdc-therapy. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab